Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAT Phathom Pharmaceuticals

Post-Market Trading 11-21 19:26:27 EST

9.45

+0.72

+8.25%

盘后9.54

+0.09+0.95%

17:42 EST

High9.62	Low8.61	Vol1.08M
Open8.67	D1 Closing8.73	Amplitude11.57%
Mkt Cap646.17M	Tradable Cap526.84M	Total Shares68.38M
T/O10.06M	T/O Rate1.95%	Tradable Shares55.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PHAT","market":"US","secType":"STK","nameCN":"Phathom Pharmaceuticals","latestPrice":9.45,"timestamp":1732222800000,"preClose":8.73,"halted":0,"volume":1084888,"hourTrading":{"tag":"盘后","latestPrice":9.54,"preClose":9.45,"latestTime":"17:42 EST","volume":12740,"amount":120419.0533,"timestamp":1732228947953},"delay":0,"floatShares":55750700,"shares":68377360,"eps":-5.6813,"marketStatus":"Post-Market Trading","change":0.72,"latestTime":"11-21 19:26:27 EST","open":8.67,"high":9.62,"low":8.61,"amount":10056591.71804,"amplitude":0.115693,"askPrice":9.87,"askSize":100,"bidPrice":9,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-5.6813,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1732237200000},"marketStatusCode":4,"adr":0,"listingDate":1571976000000,"exchange":"NASDAQ","adjPreClose":8.73,"preHourTrading":{"tag":"盘前","latestPrice":8.73,"preClose":8.73,"latestTime":"09:28 EST","volume":279,"amount":2425.330818,"timestamp":1732199334045},"postHourTrading":{"tag":"盘后","latestPrice":9.54,"preClose":9.45,"latestTime":"17:42 EST","volume":12740,"amount":120419.0533,"timestamp":1732228947953},"volumeRatio":0.674447,"impliedVol":0.33,"impliedVolPercentile":0.0437},"requestUrl":"/m/hq/s/PHAT","defaultTab":"news","newsList":[{"id":"2484971799","title":"Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2484971799","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484971799?lang=en_us&edition=fundamental","pubTime":"2024-11-20 01:00","pubTimestamp":1732035611,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals, Inc.  appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 . An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.As such, the Zacks rating upgrade for Phathom Pharmaceuticals is essentially a positive comment on its earnings outlook that could h","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UYup8AGIrn99rMsHiTllqA--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UYup8AGIrn99rMsHiTllqA--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phathom-pharmaceuticals-phat-upgraded-buy-170011997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHAT"],"gpt_icon":0},{"id":"2482243181","title":"Phathom Pharmaceuticals (PHAT) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2482243181","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482243181?lang=en_us&edition=fundamental","pubTime":"2024-11-11 10:05","pubTimestamp":1731290746,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) on November 8 and set a price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/phathom-pharmaceuticals-phat-receives-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/phathom-pharmaceuticals-phat-receives-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","BK4007","PHAT","BK4127"],"gpt_icon":0},{"id":"2481127221","title":"Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2481127221","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481127221?lang=en_us&edition=fundamental","pubTime":"2024-11-08 19:02","pubTimestamp":1731063769,"startTime":"0","endTime":"0","summary":"Net Revenues: $16.4 million for Q3 2024, representing over 120% sequential quarter-over-quarter increase.Gross Profit: $14 million, with a gross margin of 86%, an increase of about 440 basis points over last quarter.R&D Expenses: Non-GAAP R&D spend of $7.4 million, a 32% decrease compared to Q3 2023.SG&A Expenses: Non-GAAP expenses of $71.8 million for Q3 2024, with advertising costs of approximately $17.5 million.Net Loss: Non-GAAP adjusted net loss of $67.9 million or $1.05 loss per share for Q3 2024.Cash and Cash Equivalents: $335 million as of September 30, 2024.Prescriptions Filled: Over 143,000 prescriptions filled from launch through October 25th, with approximately 69,000 filled in Q3 2024.Commercial Coverage: VOQUEZNA's total covered population now captures over an estimated 120 million people or more than 80% of all US commercial lives.Phathom Pharmaceuticals Inc  successfully launched VOQUEZNA for non-erosive GERD, achieving significant market penetration with over 143,000 p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/AFsR2BeTDqarwJliTTj03A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/867ea8ef0c915a0d9ee8563b62d04207","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/AFsR2BeTDqarwJliTTj03A--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/867ea8ef0c915a0d9ee8563b62d04207"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phathom-pharmaceuticals-inc-phat-q3-110249525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHAT"],"gpt_icon":0},{"id":"2481121900","title":"Phathom Pharmaceuticals  : Craig-Hallum  Raises Target Price to $27 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2481121900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481121900?lang=en_us&edition=fundamental","pubTime":"2024-11-08 18:32","pubTimestamp":1731061960,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nAZN2LB0K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2481293132","title":"Phathom Pharmaceuticals Shares Fall After Q3 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2481293132","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481293132?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:34","pubTimestamp":1730993654,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals'  shares were down 3.3% in recent Thursday trading after the company reported a Q3 net loss of $1.05 per diluted share, wider than a loss of $0.54 a year earlier.Two analysts polled by Capital IQ projected a loss of $1.47 per share.Net revenue for the quarter ended Sept. 30 was $16.4 million, with no year-ago revenue reported.Analysts surveyed by Capital IQ expect $12.4 million.\"There were no revenues for the third quarter 2023 due to the launch of Voquezna taking place in the fourth quarter 2023,\" according to the company.Phathom received approval from the US Food and Drug Administration in July for Voquezna tablets for the relief of heartburn related to non-erosive gastroesophageal reflux disease in adults.Price: 17.41, Change: -0.59, Percent Change: -3.31","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2481184645","title":"Phathom Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2481184645","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481184645?lang=en_us&edition=fundamental","pubTime":"2024-11-07 23:10","pubTimestamp":1730992243,"startTime":"0","endTime":"0","summary":"* Phathom Pharmaceuticals Inc    reported a quarterly adjusted loss of $1.32 per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -76 c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0},{"id":"1114945777","title":"Stock Track | Phathom Pharmaceuticals' VOQUEZNA Momentum Drives 5.5% Stock Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1114945777","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114945777?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:50","pubTimestamp":1730991033,"startTime":"0","endTime":"0","summary":"Shares of Phathom Pharmaceuticals Inc.  soared by 5.5% on Tuesday, fueled by the biopharmaceutical company's impressive third-quarter financial results and promising updates on its lead product, VOQUEZNA , a novel treatment for gastrointestinal diseases.Phathom reported better-than-expected revenue of $16.4 million for the third quarter, driven by strong demand for VOQUEZNA and its associated treatment packs. Net product sales surged by over 120% compared to the previous quarter, reflecting the ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAT"],"gpt_icon":0},{"id":"2481897187","title":"Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481897187","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481897187?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:20","pubTimestamp":1730989209,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals, Inc.  came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.57. This compares to loss of $0.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 15.92%. A quarter ago, it was expected that this company would post a loss of $1.20 per share when it actually produced a loss of $1.25, delivering a surprise of -4.17%.Phathom Pharmaceuticals , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $16.35 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 30.43%. This compares to zero revenues a year ago.Phathom Pharmaceuticals shares have added about 97.2% since the beginning of the year versus the S&P 500's gain of 24.3%.While Phathom Pharmaceuticals has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hYDVEF34jJNULlluFRTwjg--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hYDVEF34jJNULlluFRTwjg--~B/aD05MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/39dfb058875b6e691de9136bc97a47b4"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phathom-pharmaceuticals-inc-phat-reports-142009393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PHAT"],"gpt_icon":0},{"id":"1169774213","title":"Stock Track | Phathom Pharmaceuticals Stock Soars Pre-Market on Impressive Q3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1169774213","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169774213?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:10","pubTimestamp":1730985022,"startTime":"0","endTime":"0","summary":"Shares of Phathom Pharmaceuticals  soared over 5% in pre-market trading today, following the company's release of its third-quarter 2024 financial results that handily beat Wall Street expectations.For the quarter ended September 30, 2024, Phathom reported an adjusted net loss of $1.05 per share, significantly better than the consensus analyst estimate of a $1.50 loss per share. The company's revenue came in at $16.352 million, surpassing the $12.609 million analysts had projected.The strong qua","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PHAT"],"gpt_icon":0},{"id":"2481904349","title":"Phathom Pharmaceuticals Q3 2024 Adj. EPS $(1.05) Beats $(1.50) Estimate, Sales $16.352M Beat $12.609M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904349","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904349?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:04","pubTimestamp":1730984664,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.50) by 30 percent. This is a 94.44 percent decrease over losses of $(0.54) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41805363/phathom-pharmaceuticals-q3-2024-adj-eps-1-05-beats-1-50-estimate-sales-16-352m-beat-12-609m-estimat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Phathom Pharmaceuticals Q3 2024 Adj. EPS $(1.05) Beats $(1.50) Estimate, Sales $16.352M Beat $12.609M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0},{"id":"2481145901","title":"BRIEF-Phathom Pharmaceuticals Q3 Net Income USD -85.577 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481145901","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481145901?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984449,"startTime":"0","endTime":"0","summary":"BRIEF-Phathom Pharmaceuticals Q3 Net Income USD -85.577 Million\n\n\nNov 07 (Reuters) - Phathom Pharmaceuticals Q3 basic EPS USD -1.32.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nPLXBFC07F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHAT","USD"],"gpt_icon":0},{"id":"2481904330","title":"Phathom Pharmaceuticals Qtrly Net REV $16.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904330?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA6WL90T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2481043649","title":"Phathom Pharmaceuticals Qtrly Adj Net Loss per Share $1.05","url":"https://stock-news.laohu8.com/highlight/detail?id=2481043649","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481043649?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nTUA6WL90T:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2481409901","title":"Phathom Pharmaceuticals Q3 Basic EPS USD -1.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2481409901","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481409901?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nPLXBFC07F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2481904734","title":"Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904734","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904734?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984400,"startTime":"0","endTime":"0","summary":"Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly increase. Over 143,000 prescriptions filled for VOQUEZNA  products, launch to date, a 138% increase since last quarterly report. Commercial access for VOQUEZNA tablets expanded, now covering over 80% of U.S. commercial lives. Management to host conference call today, November 7, 2024, at 8:30 am ET. FLORHAM PARK, N.J., Nov. 07, 2024  -- Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal  diseases, today reported financial results for the third quarter of 2024, and provided recent business updates.Recent Business Highlights and Third Quarter 2024 Results:. As the launch progresses, VOQUEZNA’s prescriber base continues to expand with the number of VOQUEZNA prescribers growing to more than 13,600 cumulative prescribers as of October 18, 2024, up from 8,2","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/C19l2dPOictaHCqwkLccXQ--~B/aD04Nzt3PTMwMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/66405a6380cdedaee9ae5700ed7d5450","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/C19l2dPOictaHCqwkLccXQ--~B/aD04Nzt3PTMwMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/66405a6380cdedaee9ae5700ed7d5450"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phathom-pharmaceuticals-reports-third-quarter-130000395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU1165135440.EUR","BK4007","LU2413666699.HKD","BK4588","PHAT","LU2092937221.SGD","LU1721428933.USD","A","LU0347712357.USD","LU2041044095.USD","LU1543694498.USD","LU2413666426.HKD","BK4567","BK4121"],"gpt_icon":0},{"id":"2480930046","title":"Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2480930046","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480930046?lang=en_us&edition=fundamental","pubTime":"2024-11-04 21:00","pubTimestamp":1730725200,"startTime":"0","endTime":"0","summary":"FLORHAM PARK, N.J., Nov. 04, 2024  -- Phathom Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal  diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December:. Guggenheim’s Inaugural Healthcare Innovation Conference in Boston, MADate: Tuesday, November 12, 2024Live Webcast: 9:30 am ETManagement to participate in one-on-one meetings throughout the conference. Stifel 2024 Healthcare Conference in New York, NYDate: Monday, November 18, 2024Live Webcast: 1:15 pm ETManagement to participate in one-on-one meetings throughout the conference. Jefferies London Healthcare Conference in London, UKDate: Wednesday, November 20, 2024Management to participate in one-on-one meetings throughout the conference. 2024 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceutica","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZZjgBfCfR2EFito9zxenXg--~B/aD0zNjg7dz03ODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5e775b8471203dec2f87473ea6e6c68e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZZjgBfCfR2EFito9zxenXg--~B/aD0zNjg7dz03ODQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5e775b8471203dec2f87473ea6e6c68e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phathom-pharmaceuticals-participate-upcoming-investor-130000885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2480884254","title":"Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480884254","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480884254?lang=en_us&edition=fundamental","pubTime":"2024-11-01 21:36","pubTimestamp":1730468219,"startTime":"0","endTime":"0","summary":"If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boost your returns by picking above-average stocks. For example, the Phathom Pharmaceuticals, Inc.  share price is up 96% in the last 1 year, clearly besting the market return of around 30% . That's a solid performance by our standards!In contrast, the longer term returns are negative, since the share price is 23% lower than it was three years ago.Since the stock has added US$75m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.Given that Phathom Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.The image below shows how earnings and revenue have tra","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-bid-phathom-pharmaceuticals-nasdaq-133659353.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKPKM429.USD","PSQ","LU2095319765.USD","MNQmain","QID","NDAQ","NQmain","TQQQ",".IXIC","BK4588","BK4112","IE00BGHQF748.EUR","SQQQ","LU2210150020.SGD","QLD","BK4007","IE00B64PRP62.GBP","BK4585","BK4211","LU2210149790.SGD","ISBC","IE00B3QW5Z07.USD","PHAT"],"gpt_icon":1},{"id":"2478104803","title":"BRIEF-Phathom Pharmaceuticals To Report Third Quarter 2024 Financial Results And Provide Business Update On Thursday, November 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478104803","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478104803?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:02","pubTimestamp":1730116927,"startTime":"0","endTime":"0","summary":"Oct 28 (Reuters) - Phathom Pharmaceuticals Inc   :   * PHATHOM PHARMACEUTICALS TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON THURSDAY, NOVEMBER 7, 2024Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","LU1720051017.SGD","LU1861215975.USD","LU0724618433.USD","LU1854104046.USD","LU2298322129.HKD","LU2360107325.USD","LU0124384867.USD","BK4585","ON","LU1978683503.SGD","PHAT","IE00BD6J9T35.USD","LU1861214812.USD","IE00BZ199S13.USD","LU2357305700.SGD","LU0348723411.USD","BK4141","LU1861219969.SGD","BK4512","LU1720051108.HKD","BK4007","LU1861220033.SGD","BK4588","LU1854103824.USD"],"gpt_icon":0},{"id":"2478010091","title":"Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478010091","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478010091?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:00","pubTimestamp":1730116849,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241028:nTUATJJZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2478049921","title":"Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478049921","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478049921?lang=en_us&edition=fundamental","pubTime":"2024-10-28 20:00","pubTimestamp":1730116800,"startTime":"0","endTime":"0","summary":"Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Oct.  28, 2024  (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/28/2970035/0/en/Phathom-Pharmaceuticals-to-Report-Third-Quarter-2024-Financial-Results-and-Provide-Business-Update-on-Thursday-November-7-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PHAT"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phathompharma.com","stockEarnings":[{"period":"1week","weight":-0.1046},{"period":"1month","weight":-0.4375},{"period":"3month","weight":-0.3185},{"period":"6month","weight":-0.1686},{"period":"1year","weight":0.2108},{"period":"ytd","weight":-0.0438}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":0.0118},{"period":"3month","weight":0.0616},{"period":"6month","weight":0.1153},{"period":"1year","weight":0.3028},{"period":"ytd","weight":0.2423}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.023646},{"month":2,"riseRate":0.8,"avgChangeRate":0.124053},{"month":3,"riseRate":0,"avgChangeRate":-0.171034},{"month":4,"riseRate":0.6,"avgChangeRate":0.127165},{"month":5,"riseRate":0.6,"avgChangeRate":-0.027307},{"month":6,"riseRate":0.6,"avgChangeRate":0.044836},{"month":7,"riseRate":0.8,"avgChangeRate":0.051978},{"month":8,"riseRate":0.6,"avgChangeRate":0.096985},{"month":9,"riseRate":0.4,"avgChangeRate":0.002397},{"month":10,"riseRate":0.2,"avgChangeRate":-0.078312},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.143946},{"month":12,"riseRate":0.8,"avgChangeRate":0.103809}],"exchange":"NASDAQ","name":"Phathom Pharmaceuticals","nameEN":"Phathom Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phathom Pharmaceuticals,PHAT,Phathom Pharmaceuticals股票,Phathom Pharmaceuticals股票老虎,Phathom Pharmaceuticals股票老虎国际,Phathom Pharmaceuticals行情,Phathom Pharmaceuticals股票行情,Phathom Pharmaceuticals股价,Phathom Pharmaceuticals股市,Phathom Pharmaceuticals股票价格,Phathom Pharmaceuticals股票交易,Phathom Pharmaceuticals股票购买,Phathom Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}